Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory prospective observational study to compare th...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuki Oe, Hiroshi Nomoto, Akinobu Nakamura, Saki Kuwabara, Yuka Takahashi, Ayano Yasui, Rimi Izumihara, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	Journal of Diabetes Research
Online Access:	http://dx.doi.org/10.1155/2022/5603864
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-07-01)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)

Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine
by: Natalie Rosario, et al.
Published: (2025-03-01)

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK
by: Nandu Thalange, et al.
Published: (2019-05-01)

Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials
by: Wei Liu, et al.
Published: (2018-01-01)

The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
by: M. V. Shestakova, et al.
Published: (2021-07-01)

Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes
by: Aika Miya, et al.
Published: (2024-04-01)

Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
by: Marina Vladimirovna Shestakova, et al.
Published: (2015-12-01)

Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
by: Lyudmila Alexandrovna Suplotova, et al.
Published: (2015-12-01)

A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300
by: Oppel B.W. Greeff, et al.
Published: (2018-08-01)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
by: Kyu Yong Cho, et al.
Published: (2022-05-01)

Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis
by: Saaed Abunada, et al.
Published: (2025-07-01)

Metabolic adaptation to acute metabolic stress via PFKFB3 upregulation in rodent beta cells
by: Koki Chiba, et al.
Published: (2025-06-01)

The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia
by: G. R. Galstyan
Published: (2023-02-01)

Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes
by: Sezin Dogan Çakır, et al.
Published: (2025-08-01)

Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study
by: Yuka Tosaka, et al.
Published: (2015-01-01)

A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa
by: Mark T. Verryn, et al.
Published: (2025-03-01)

Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression
by: Amr Ahmed, et al.
Published: (2024-07-01)

Positive association between proinsulin and fatty liver index in people with type 2 diabetes
by: Akinobu Nakamura, et al.
Published: (2024-02-01)

Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study
by: Liu H, et al.
Published: (2025-04-01)

Effects of insulin glargine U300 versus insulin degludec U100 on glycemic variability, hypoglycemia, and diet evaluated by continuous glucose monitoring in type 1 diabetes: a retrospective cross‐sectional study
by: Pin‐Lun Tsai, et al.
Published: (2024-12-01)

Dipeptidyl peptidase-1 inhibitors in bronchiectasis
by: Emma Johnson, et al.
Published: (2025-06-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Esaxerenone improves the blood pressure and metabolic parameters of hypertensive subjects with diabetes
by: Saki Kuwabara, et al.
Published: (2025-08-01)

SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
by: M. Ganeva
Published: (2023-03-01)

Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy
by: Cristiano S. Moura, et al.
Published: (2018-01-01)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01)

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
by: Sho Furusawa, et al.
Published: (2024-06-01)

Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
by: Gail Mkele
Published: (2013-12-01)

Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor
by: Vladimir Pech, et al.
Published: (2015-01-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration
by: Yu Tian, et al.
Published: (2023-12-01)

The Potential of some Plant Extracts as Radical Scavengers and Dipeptidyl Peptidase-4 Inhibitors
by: Malik et al.
Published: (2019-03-01)

Curcumin inhibits growth of Porphyromonas gingivalis by arrest of bacterial dipeptidyl peptidase activity
by: Hiroki Murai, et al.
Published: (2024-12-01)

Retrospective trial of long acting analogues detemir and degludec usage in children and adolescents to overcome glucose variability caused by dawn phenomenon and reverse dawn phenomenon
by: A. V. Vitebskaya, et al.
Published: (2021-11-01)

Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus
by: Masashi Shimoda, et al.
Published: (2017-01-01)

Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
by: Carlos K H Wong, et al.
Published: (2019-12-01)

Effects of liraglutide on 8-OHdG,MDA and SOD of kidney in insulin resistance rats
by: WU Ming-hao, et al.
Published: (2017-01-01)

Effects of Dipeptidyl Peptidase-4 Inhibition with MK-0431 on Syngeneic Mouse Islet Transplantation
by: Jyuhn-Huarng Juang, et al.
Published: (2014-01-01)

Preparation and Purification of Dipeptidyl Peptidase-IV Inhibitory Peptides from Pearl Mussel Muscle
by: ZHANG Chuhan, CHEN Yinge, MA Ting, WENG Ling, ZHANG Lingjing, ZHANG Genfang, CAO Minjie
Published: (2024-09-01)